Question 1

What is carbamoyl phosphate synthetase I deficiency disease?

Accepted Answer

Carbamoyl phosphate synthetase I deficiency disease is a severe metabolic disorder that disrupts the urea cycle and results in the accumulation of toxic levels of ammonia in the body. It is caused by pathogenic variants in the CPS1 gene, which encodes an enzyme critical for converting ammonia to urea. Affected individuals often present during the neonatal period with severe hyperammonemia, although later-onset presentations with milder symptoms may also occur. Because precise prevalence estimates are not well established, the condition is understood to be very rare.

Question 2

What are the symptoms of carbamoyl phosphate synthetase I deficiency disease?

Accepted Answer

The clinical presentation commonly begins with lethargy and progresses to severe episodes of hyperammonemia, which can manifest as seizures, respiratory insufficiency, and hypotonia. Along with these acute metabolic crises, affected individuals may experience neurological challenges that impact developmental progress and, in some cases, cognitive functioning. Other features such as episodic symptoms of ammonia intoxication, hypoargininemia, and even stroke in a subset of patients highlight the varied nature of this disorder. Not all individuals experience all features, and severity varies considerably.

Question 3

What causes carbamoyl phosphate synthetase I deficiency disease?

Accepted Answer

Carbamoyl phosphate synthetase I deficiency disease is caused by pathogenic variants in the CPS1 gene. The CPS1 gene codes for an enzyme essential in the urea cycle, responsible for converting ammonia into urea, thereby preventing toxic buildup. This condition is inherited in an autosomal recessive pattern, which means that an affected individual must inherit two abnormal copies of the CPS1 gene, one from each parent. Parents are typically unaffected carriers, and there is a one in four chance with each pregnancy for an affected child to be born. Associated genes include CPS1.

Question 4

How is carbamoyl phosphate synthetase I deficiency disease inherited?

Accepted Answer

carbamoyl phosphate synthetase I deficiency disease follows an autosomal recessive inheritance pattern. This means a child must inherit a copy of the altered gene from both parents to develop the condition. Parents who each carry one copy typically do not show symptoms.

Question 5

How rare is carbamoyl phosphate synthetase I deficiency disease?

Accepted Answer

carbamoyl phosphate synthetase I deficiency disease is classified as not well established. The estimated prevalence is approximately Unknown. Because rare disease data can be limited, actual numbers may differ from published estimates.

Question 6

How is carbamoyl phosphate synthetase I deficiency disease diagnosed?

Accepted Answer

Diagnosis is confirmed through molecular genetic testing that identifies pathogenic variants in the CPS1 gene. Alongside genetic testing, clinical evaluation of symptoms such as severe hyperammonemia, lethargy, and seizures is essential for distinguishing this condition from other metabolic disorders. Given that many metabolic conditions can present similarly, comprehensive genetic analysis remains the gold standard for an accurate diagnosis.

Question 7

Are there treatments for carbamoyl phosphate synthetase I deficiency disease?

Accepted Answer

Currently, management for carbamoyl phosphate synthetase I deficiency disease focuses on supportive care and symptom management. Treatment strategies are aimed at reducing blood ammonia levels through dietary management, medications to stabilize metabolism, and prompt intervention during episodes of hyperammonemia. As there are no FDA-approved treatments specifically for this condition, care is tailored by a multidisciplinary team to address the individual needs of the patient. Genetic counseling is recommended to help families understand the implications of this autosomal recessive condition and to explore available management options with their healthcare team.

Question 8

Are there clinical trials for carbamoyl phosphate synthetase I deficiency disease?

Accepted Answer

Yes, there are currently 3 active clinical trials for carbamoyl phosphate synthetase I deficiency disease registered on ClinicalTrials.gov. Clinical trials test new treatments, procedures, or approaches. Your healthcare provider can help determine if a trial might be appropriate for your situation. Visit the Treatment section of this page for more details.

Question 9

What are the potential complications of carbamoyl phosphate synthetase I deficiency disease?

Accepted Answer

Complications from carbamoyl phosphate synthetase I deficiency disease can include severe hyperammonemia, which may lead to seizures, respiratory problems, and hypotonia. Some individuals may also experience neurological challenges that affect their development and cognitive abilities. In certain cases, patients can suffer from stroke due to the effects of ammonia on the brain.

Question 10

How does carbamoyl phosphate synthetase I deficiency disease affect daily life?

Accepted Answer

Living with carbamoyl phosphate synthetase I deficiency disease often requires careful management of diet and regular monitoring of ammonia levels. Families may need to be prepared for medical emergencies, especially during episodes of hyperammonemia. Support from a multidisciplinary care team can help families navigate daily challenges and ensure the best possible quality of life.

Question 11

What is the long-term outlook for someone with carbamoyl phosphate synthetase I deficiency disease?

Accepted Answer

The long-term outlook for individuals with carbamoyl phosphate synthetase I deficiency disease can vary widely. Many people can stabilize after initial treatment for hyperammonemia, but they may continue to face neurological challenges. Ongoing care and support from specialists can help manage these issues and improve overall outcomes.

Question 12

What should families consider regarding future pregnancies if one child has carbamoyl phosphate synthetase I deficiency disease?

Accepted Answer

If a family has one child with carbamoyl phosphate synthetase I deficiency disease, they should consider genetic counseling for future pregnancies. Since the condition is inherited in an autosomal recessive pattern, there is a one in four chance with each pregnancy for another affected child. Genetic counselors can provide valuable information about risks and options for family planning.

Organ System	Phenotype Count	Example Features
Brain and nerves	7	Stroke, Seizure, Global developmental delay
Lungs and breathing	2	Respiratory alkalosis, Difficulty breathing (respiratory insufficiency)
Heart and blood vessels	1	Stroke
Digestive system	1	Vomiting
Growth and development	1	Failure to thrive
Muscles	1	Low muscle tone (hypotonia)

Research Type	Count	% of Total
Research summaries	3	27%
Patient case studies	2	18%
Laboratory research	2	18%
Disease patterns and progression	2	18%
Testing and diagnosis research	1	9%
New treatment approaches	1	9%

Kisho

carbamoyl phosphate synthetase I deficiency disease

Overview

Clinical Presentation

Explore clinical features

Genetic Landscape

Diagnosis

Prognosis

Research Landscape

Recent Publications

Medical References

External Resources

OMIM

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

Latest News & Developments

Breakthrough Gene Therapy Saves Infant With Rare Metabolic Disease | Managed Healthcare Executive

carbamoyl phosphate synthetase I deficiency disease

Overview

Clinical Presentation

Explore clinical features

Genetic Landscape

Diagnosis

Prognosis

Research Landscape

Recent Publications

Medical References

External Resources

OMIM

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

What is carbamoyl phosphate synthetase I deficiency disease?

What are the symptoms of carbamoyl phosphate synthetase I deficiency disease?

What causes carbamoyl phosphate synthetase I deficiency disease?

How is carbamoyl phosphate synthetase I deficiency disease inherited?

How rare is carbamoyl phosphate synthetase I deficiency disease?

How is carbamoyl phosphate synthetase I deficiency disease diagnosed?

Are there treatments for carbamoyl phosphate synthetase I deficiency disease?

Are there clinical trials for carbamoyl phosphate synthetase I deficiency disease?

What are the potential complications of carbamoyl phosphate synthetase I deficiency disease?

How does carbamoyl phosphate synthetase I deficiency disease affect daily life?

What is the long-term outlook for someone with carbamoyl phosphate synthetase I deficiency disease?

What should families consider regarding future pregnancies if one child has carbamoyl phosphate synthetase I deficiency disease?

Latest News & Developments

Breakthrough Gene Therapy Saves Infant With Rare Metabolic Disease | Managed Healthcare Executive